Wednesday November 4, 2020 0 comments
DENVER -- Biodesix, Inc. announced the closing of its initial public offering of 4 million shares of its common stock at a public offering price of $18 per share.
The gross proceeds to Biodesix, before deducting underwriting discounts and commissions, were approximately $72 million.
The shares began trading on The Nasdaq Global Market on Oct. 28 under the symbol “BDSX.”
Morgan Stanley and William Blair acted as lead book-running managers for the offering. Canaccord Genuity acted as lead manager and BTIG acted as co-manager for the offering.
The offering was made only by means of a prospectus.
Copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at [email protected] or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at [email protected]
A registration statement relating to the shares being sold in this offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.